Breast Cancer Coverage from Every Angle

Antonio Marra, MD, on Clinical Implications of Genomic Instability and Treatment of Advanced Breast Cancer

Posted: Sunday, September 11, 2022

Antonio Marra, MD, of Memorial Sloan Kettering Cancer Center, discusses the clinical challenges of resistance to endocrine therapy with or without CDK4/6 inhibition in otherwise eligible patients with estrogen receptor–positive/HER2-negative metastatic breast cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.